These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 20398864)

  • 1. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation.
    Suh J; Park DW; Lee JY; Jung IH; Lee SW; Kim YH; Lee CW; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2010 Apr; 3(4):383-9. PubMed ID: 20398864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stent thrombosis, clinical events, and influence of prolonged clopidogrel use after placement of drug-eluting stent data from an observational cohort study of drug-eluting versus bare-metal stents.
    Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Cheong SS; Kim JJ; Park SW; Park SJ
    JACC Cardiovasc Interv; 2008 Oct; 1(5):494-503. PubMed ID: 19463351
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of drug-eluting stent thrombosis in patients receiving proton pump inhibitors.
    Sarafoff N; Sibbing D; Sonntag U; Ellert J; Schulz S; Byrne RA; Mehilli J; Schömig A; Kastrati A
    Thromb Haemost; 2010 Sep; 104(3):626-32. PubMed ID: 20664905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The unrestricted use of sirolimus- and paclitaxel-eluting stents results in better clinical outcomes during 6-year follow-up than bare-metal stents: an analysis of the RESEARCH (Rapamycin-Eluting Stent Evaluated At Rotterdam Cardiology Hospital) and T-SEARCH (Taxus-Stent Evaluated At Rotterdam Cardiology Hospital) registries.
    Simsek C; Magro M; Boersma E; Onuma Y; Nauta ST; Gaspersz MP; van der Giessen WJ; van Domburg RT; Serruys PW;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1051-8. PubMed ID: 20965464
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
    Naidu SS; Krucoff MW; Rutledge DR; Mao VW; Zhao W; Zheng Q; Wilburn O; Sudhir K; Simonton C; Hermiller JB
    JACC Cardiovasc Interv; 2012 Jun; 5(6):626-35. PubMed ID: 22721657
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective drug-eluting stent implantation for high-risk patients with acute ST-elevation myocardial infarction: rationale and safety.
    Prasad SB; David T; Malaiapan Y; Cameron JD; Meredith IT
    Catheter Cardiovasc Interv; 2011 Feb; 77(2):193-200. PubMed ID: 20549694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial.
    Vink MA; Dirksen MT; Suttorp MJ; Tijssen JG; van Etten J; Patterson MS; Slagboom T; Kiemeneij F; Laarman GJ
    JACC Cardiovasc Interv; 2011 Jan; 4(1):24-9. PubMed ID: 21251625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and predictors of very late (>or=4 years) major cardiac adverse events in the DESIRE (Drug-Eluting Stents in the Real World)-Late registry.
    Costa JR; Sousa A; Moreira AC; Costa RA; Cano M; Maldonado G; Campos C; Carballo M; Pavanello R; Sousa JE
    JACC Cardiovasc Interv; 2010 Jan; 3(1):12-8. PubMed ID: 20129562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year clinical outcomes in patients with chronic renal failure treated by percutaneous coronary intervention with drug-eluting stent.
    Barthelemy O; Helft G; Silvain J; Bellemain-Appaix A; Beygui F; Choussat R; Berman E; Collet JP; Montalescot G; Metzger JP; Le Feuvre C
    Arch Cardiovasc Dis; 2011 Dec; 104(12):604-10. PubMed ID: 22152512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 3-year clinical outcome of patients with chronic total occlusion treated with drug-eluting stents.
    De Felice F; Fiorilli R; Parma A; Nazzaro M; Musto C; Sbraga F; Caferri G; Violini R
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1260-5. PubMed ID: 20129553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of drug-eluting and bare-metal stents for primary percutaneous coronary intervention with or without abciximab in ST-segment elevation myocardial infarction: DEBATER: the Eindhoven reperfusion study.
    Wijnbergen I; Helmes H; Tijssen J; Brueren G; Peels K; van Dantzig JM; Van' t Veer M; Koolen JJ; Pijls NH; Michels R
    JACC Cardiovasc Interv; 2012 Mar; 5(3):313-22. PubMed ID: 22440498
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized comparison of sirolimus- versus paclitaxel-eluting stent implantation in patients with diabetes mellitus: 4-year clinical outcomes of DES-DIABETES (drug-eluting stent in patients with DIABETES mellitus) trial.
    Lee SW; Park SW; Kim YH; Yun SC; Park DW; Lee CW; Kang SJ; Rhee KS; Chae JK; Ko JK; Park JH; Lee JH; Choi SW; Jeong JO; Seong IW; Cho YH; Lee NH; Kim JH; Chun KJ; Kim HS; Park SJ
    JACC Cardiovasc Interv; 2011 Mar; 4(3):310-6. PubMed ID: 21435609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sirolimus-eluting coronary stents in octogenarians: a 1-year analysis of the worldwide e-SELECT Registry.
    Hong YJ; Jeong MH; Abizaid A; Banning A; Bartorelli A; Dzavik V; Ellis SG; Gao R; Holmes DR; Legrand V; Neumann FJ; Spaulding C; Worthley S; Urban P;
    JACC Cardiovasc Interv; 2011 Sep; 4(9):982-91. PubMed ID: 21939938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 5 years follow-up from the randomized DEDICATION trial (Drug Elution and Distal Protection in Acute Myocardial Infarction).
    Holmvang L; Kelbæk H; Kaltoft A; Thuesen L; Lassen JF; Clemmensen P; Kløvgaard L; Engstrøm T; Bøtker HE; Saunamäki K; Krusell LR; Jørgensen E; Tilsted HH; Christiansen EH; Ravkilde J; Køber L; Kofoed KF; Terkelsen CJ; Helqvist S
    JACC Cardiovasc Interv; 2013 Jun; 6(6):548-53. PubMed ID: 23683734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes and complications with off-label use of drug-eluting stents: results from the STENT (Strategic Transcatheter Evaluation of New Therapies) group.
    Brodie BR; Stuckey T; Downey W; Humphrey A; Bradshaw B; Metzger C; Hermiller J; Krainin F; Juk S; Cheek B; Duffy P; Smith H; Edmunds J; Varanasi J; Simonton CA;
    JACC Cardiovasc Interv; 2008 Aug; 1(4):405-14. PubMed ID: 19463338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term safety and efficacy with paclitaxel-eluting stents: 5-year final results of the TAXUS IV clinical trial (TAXUS IV-SR: Treatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting Stent).
    Ellis SG; Stone GW; Cox DA; Hermiller J; O'Shaughnessy C; Mann T; Turco M; Caputo R; Bergin PJ; Bowman TS; Baim DS;
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1248-59. PubMed ID: 20129552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of stent thrombosis in patients with acute coronary syndromes treated with bare-metal and drug-eluting stents.
    Kukreja N; Onuma Y; Garcia-Garcia HM; Daemen J; van Domburg R; Serruys PW;
    JACC Cardiovasc Interv; 2009 Jun; 2(6):534-41. PubMed ID: 19539258
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of percutaneous coronary intervention for chronic total occlusions.
    Mehran R; Claessen BE; Godino C; Dangas GD; Obunai K; Kanwal S; Carlino M; Henriques JP; Di Mario C; Kim YH; Park SJ; Stone GW; Leon MB; Moses JW; Colombo A;
    JACC Cardiovasc Interv; 2011 Sep; 4(9):952-61. PubMed ID: 21939934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.